Pomalyst vs Januvia
Side-by-side drug price comparison from Medicare Part D data
Verdict
Januvia costs 99% less per claim than Pomalyst ($219.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Januvia at $2.7B.
| Metric | Pomalyst | Januvia |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $17,250 | $219* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.3B | $2.7B |
| Total Claims | 192,000 | 12,480,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 4.7% | -12.3%* |
| Generic Available | No | No |
| Condition | Cancer | Diabetes |
| Total Beneficiaries | 18,000 | 1,560,000 |
Januvia costs 99% less per claim than Pomalyst ($219.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Pomalyst at $3.3B vs Januvia at $2.7B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Pomalyst and Januvia. What follows is the interpretation — which specific axes carry the most weight for Pomalyst versus Januvia, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.